Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Chem Soc ; 143(15): 5659-5665, 2021 04 21.
Article in English | MEDLINE | ID: mdl-33825486

ABSTRACT

The incorporation of carbon-14 allows tracking of organic molecules and provides vital knowledge on their fate. This information is critical in pharmaceutical development, crop science, and human food safety evaluation. Herein, a transition-metal-catalyzed procedure enabling carbon isotope exchange on aromatic nitriles is described. By utilizing the radiolabeled precursor Zn([14C]CN)2, this protocol allows the insertion of the desired carbon tag without the need for structural modifications, in a single step. By reducing synthetic costs and limiting the generation of radioactive waste, this procedure will facilitate the labeling of nitrile containing drugs and accelerate 14C-based ADME studies supporting drug development.


Subject(s)
Pharmaceutical Preparations/chemistry , Carbon Radioisotopes/chemistry , Catalysis , Coordination Complexes/chemistry , Cycloaddition Reaction , Isotope Labeling , Molecular Conformation , Nitriles/chemistry , Transition Elements/chemistry , Zinc/chemistry
2.
Cancer Chemother Pharmacol ; 81(6): 1095-1103, 2018 06.
Article in English | MEDLINE | ID: mdl-29675746

ABSTRACT

PURPOSE: The primary aim of this study was to determine cabazitaxel's affinity for the ABCB1/P-glycoprotein (P-gp) transporter compared to first-generation taxanes. METHODS: We determined the kinetics of drug accumulation and retention using [14C]-labeled taxanes in multidrug-resistant (MDR) cells. In addition, membrane-enriched fractions isolated from doxorubicin-selected MES-SA/Dx5 cells were used to determine sodium orthovanadate-sensitive ATPase stimulation after exposure to taxanes. Custom [3H]-azido-taxane analogues were synthesized for the photoaffinity labeling of P-gp. RESULTS: The maximum intracellular drug concentration was achieved faster with [14C]-cabazitaxel (5 min) than [14C]-docetaxel (15-30 min). MDR cells accumulated twice as much cabazitaxel than docetaxel, and these levels could be restored to parental levels in the presence of the P-gp inhibitor PSC-833 (valspodar). Efflux in drug-free medium confirmed that MDR cells retained twice as much cabazitaxel than docetaxel. There was a strong association (r2 = 0.91) between the degree of taxane resistance conferred by P-gp expression and the accumulation differences observed with the two taxanes. One cell model expressing low levels of P-gp was not cross-resistant to cabazitaxel while demonstrating modest resistance to docetaxel. Furthermore, there was a 1.9 × reduction in sodium orthovanadate-sensitive ATPase stimulation resulting from treatment with cabazitaxel compared to docetaxel. We calculated a dissociation constant (Kd) value of 1.7 µM for [3H]-azido-docetaxel and ~ 7.5 µM for [3H]-azido-cabazitaxel resulting in a 4.4 × difference in P-gp labeling, and cold docetaxel was a more effective competitor than cabazitaxel. CONCLUSION: Our studies confirm that cabazitaxel is more active in ABCB1(+) cell models due to its reduced affinity for P-gp compared to docetaxel.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Antineoplastic Agents/pharmacology , Docetaxel/pharmacology , Taxoids/pharmacology , ATP Binding Cassette Transporter, Subfamily B/metabolism , Cell Line, Tumor , Cyclosporins/pharmacology , Doxorubicin/pharmacology , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Humans , Neoplasms/drug therapy , Neoplasms/pathology , Time Factors
3.
Clin Sci (Lond) ; 131(4): 261-268, 2017 02 01.
Article in English | MEDLINE | ID: mdl-28108631

ABSTRACT

Since 2012, clinical trials dedicated to proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition with monoclonal antibodies (mAbs) have unambiguously demonstrated robust reductions not only in low-density lipoprotein (LDL) cholesterol (LDL-C) but also in lipoprotein (a) [Lp(a)] levels. The scientific literature published prior to those studies did not provide any evidence for a link between PCSK9 and Lp(a) metabolism. More recent investigations, either in vitro or in vivo, have attempted to unravel the mechanism(s) by which PCSK9 mAbs reduce circulating Lp(a) levels, with some showing a specific implication of the LDL receptor (LDLR) in Lp(a) clearance whereas others found no significant role for the LDLR in that process. This elusive pathway appears clearly distinct from that of the widely prescribed statins that also enhance LDLR function but do not lower circulating Lp (a) levels in humans. So how does PCSK9 inhibition with mAbs reduce Lp(a)? This still remains to be established.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Hyperlipidemias/drug therapy , Lipoprotein(a)/blood , PCSK9 Inhibitors , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized , Humans , Hyperlipidemias/blood , Hypolipidemic Agents/pharmacology , Hypolipidemic Agents/therapeutic use , Proprotein Convertase 9/immunology , Receptors, LDL/physiology , Research Design
4.
JACC Basic Transl Sci ; 1(6): 419-427, 2016 Oct.
Article in English | MEDLINE | ID: mdl-29308438

ABSTRACT

To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and measured Lp(a) secretion from human hepatocytes. They found that Lp(a) cellular uptake occurred in a low-density lipoprotein receptor-independent manner. Neither PCSK9 nor alirocumab altered Lp(a) internalization. By contrast, the secretion of apolipoprotein (a) from human hepatocytes was sharply increased by PCSK9, an effect that was reversed by alirocumab. They propose that PCSK9 does not significantly modulate Lp(a) catabolism, but rather enhances the secretion of Lp(a) from liver cells.

5.
Am J Physiol Regul Integr Comp Physiol ; 293(2): R938-49, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17522130

ABSTRACT

[(3)H]SSR-149415 is the first tritiated nonpeptide vasopressin V(1b) receptor (V(1b)R) antagonist ligand. It was used for studying rodent (mouse, rat, hamster) and human V(1b)R from native or recombinant origin. Moreover, a close comparison between the human and the mouse V(1b)R was performed using SSR-149415/[(3)H]SSR-149415 in binding and functional studies in vitro. [(3)H]SSR-149415 binding was time-dependent, reversible, and saturable. Scatchard plot analysis gave a single class of high-affinity binding sites with apparent equilibrium dissociation constant (K(d)) approximately 1 nM and maximum binding density (B(max)) values from 7,000 to 300,000 sites/cell according to the cell line. In competition experiments, [(3)H]SSR-149415 binding was stereospecific and dose-dependently displaced by reference peptide and nonpeptide arginine vasopressin (AVP)/OT ligands following a V(1b) rank order of affinity: SSR-149415 = AVP > dCha > dPen > dPal > dDavp > SSR-126768A > SR-49059 > SSR-149424 > OT > SR-121463B. Species differences between human, rat, mouse, and hamster V(1b)R were observed. Autoradiography studies with [(3)H]SSR-149415 on rat and human pituitary showed intense specific labeling confined to corticotroph cells and absence of labeling in the other tissues examined. SSR-149415 potently and stereospecifically antagonized the AVP-induced inositol phosphate production and intracellular Ca(2+) increase (EC(50) from 1.83 to 3.05 nM) in recombinant cell lines expressing either the mouse or the human V(1b)R. AVP (10(-7) M) exposure of AtT20 cells expressing mouse or human EGFP-tagged V(1b)R induced their rapid internalization. Preincubation with 10(-6) M SSR-149415 counteracted the internalization process. Moreover, recycling of internalized receptors was observed upon 10(-6) M SSR-149415 treatment. Thus SSR-149415/[(3)H]SSR-149415 are unique tools for studying animal and human V(1b)R.


Subject(s)
Autoradiography/methods , Indoles/metabolism , Pyrrolidines/metabolism , Radioligand Assay/methods , Receptors, Vasopressin/metabolism , Animals , Calcium/metabolism , Cell Line , Cricetinae , DNA, Complementary , Endocytosis , Humans , Indoles/chemistry , Indoles/pharmacology , Inositol Phosphates/metabolism , Ligands , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mice , Pyrrolidines/chemistry , Pyrrolidines/pharmacology , Receptors, Vasopressin/genetics , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sensitivity and Specificity , Tritium
6.
Org Lett ; 4(7): 1235-8, 2002 Apr 04.
Article in English | MEDLINE | ID: mdl-11922827

ABSTRACT

[reaction: see text] Simply mixing amino alcohol A and thiol in toluene and TFA provided the corresponding amino sulfide B in excellent chemical yield and diastereoselectivity. A double SN2 process initiated by O-5 participation of the neighboring N-carbamate group was advanced to explain the overall retention of configuration at the chiral benzylic center.


Subject(s)
Amines/chemical synthesis , Benzyl Compounds/chemical synthesis , Carbamates/chemistry , Sulfides/chemical synthesis , Animals , Hydrolysis , Indicators and Reagents , Magnetic Resonance Spectroscopy , Stereoisomerism
SELECTION OF CITATIONS
SEARCH DETAIL
...